SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Obesity

PUBLISHER: Grand View Research | PRODUCT CODE: 2151496

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2151496

Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product, By Mechanism Of Action, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

The global anti-obesity medication market size was valued at USD 19.5 billion in 2025 and is projected to grow from USD 25.7 billion in 2026 to USD 176.4 billion by 2033, growing at a CAGR of 31.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. Increasing awareness of the health consequences of being overweight fuels market growth. In addition, the rising adoption of highly effective GLP-1 receptor agonists and next-generation weight loss therapies is significantly accelerating market expansion.

Accelerated development of anti-obesity drugs, supported by significant R&D investments, is expected to drive market growth. With advancements in drug development technologies, the market is poised for further growth, addressing the pressing need to combat overweight-related health challenges. In March 2025, the World Obesity Federation published the World Obesity Atlas, which projects that the number of obese adults will grow by more than 115% from 2010 to 2030, rising from 524 million to around 1.13 billion. The report states that two-thirds of countries lack most key national obesity policies, and only 7% have health systems adequately prepared to address obesity.

Furthermore, overweight and obesity are associated with approximately 1.6 million premature deaths annually from conditions including diabetes, cancer, heart disease, and stroke. The growing burden of obesity and inadequate healthcare preparedness is expected to accelerate demand for pharmacological interventions, thereby supporting market expansion. Moreover, the projected increase in obesity prevalence directly correlates with market growth, creating opportunities for pharmaceutical companies, healthcare providers, and other stakeholders. As healthcare costs associated with obesity continue to escalate, there is a growing imperative for innovative solutions and interventions to curb this epidemic and ensure sustainable healthcare cost containment.

Market players are actively investing in R&D to develop innovative medicines for weight management. For instance, in October 2025, Eli Lilly reported successful topline results from the Phase III trial, in which oral GLP-1 receptor agonist orforglipron achieved significant weight reduction and improvements in cardiometabolic risk factors in adults with obesity or overweight. These advancements are expected to intensify competition, broaden therapeutic options, and accelerate market growth.

The introduction of new medications such as CagriSema, Oral Sema Obesity, GELA, INV-202, and orforglipron is propelling the market growth. Investing in this sector enables companies to seize opportunities arising from evolving demands and gain a competitive edge. Leading the development and commercialization of innovative medications positions companies as frontrunners, consolidating their market presence.

Show more
Product Code: GVR-4-68040-235-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Mechanism of Action
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Mechanism of Action outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Obesity Medication Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Prevalence of Obesity-Related Conditions
      • 3.2.1.2. Government Regulations and Guidelines
      • 3.2.1.3. Increase in technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Side Effects and Adverse Reactions
      • 3.2.2.2. High cost of anti-obesity drugs
  • 3.3. Anti-Obesity Medication Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Anti-Obesity Medication Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Anti-Obesity Medication Market by Product Outlook
  • 4.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Approved
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.1. Bupropion-naltrexone (Contrave)
        • 4.4.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2. Liraglutide (Saxenda)
        • 4.4.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3. Orlistat
        • 4.4.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.1.3.2. Xenical
          • 4.4.1.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.1.3.3. Alli
          • 4.4.1.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.4. Phentermine-topiramate (Qsymia)
        • 4.4.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.5. Semaglutide (Wegovy)
        • 4.4.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.6. Setmelanotide (Imcivree)
        • 4.4.1.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.7. Tirzepatide (Zepbound)
        • 4.4.1.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Off Label
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.1. Semaglutide (Ozempic)
          • 4.4.2.1.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.2. Liraglutide (Victoza)
          • 4.4.2.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.3. Dulaglutide (Trulicity)
          • 4.4.2.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.4. Topiramate (Dulaglutide (Trulicity))
          • 4.4.2.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.1.5. Other
          • 4.4.2.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Anti-Obesity Medication Market: Mechanism of Action Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Anti-Obesity Medication Market Movement Analysis
  • 5.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Mechanism of Action, 2021 to 2033 (USD Million)
  • 5.4. Peripherally Acting Drugs
    • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Centrally Acting Drugs
    • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Anti-Obesity Medication Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Anti-Obesity Medication Market Movement Analysis
  • 6.3. Global Anti-Obesity Medication Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Anti-Obesity Medication Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Novo Nordisk A/S
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. VIVUS LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Currax Pharmaceuticals LLC
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Boehringer Ingelheim International GmbH
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Rhythm Pharmaceuticals, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Gelesis
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-235-6

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 North America Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 4 North America Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 5 North America Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 6 North America Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 7 U.S. Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 8 U.S. Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 9 U.S. Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 10 Canada Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 11 Canada Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 12 Canada Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 13 Europe Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 14 Europe Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 15 Europe Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 16 Europe Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 17 Germany Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 18 Germany Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 19 Germany Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20 UK Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 21 UK Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 22 UK Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 23 France Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 24 France Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 25 France Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 26 Italy Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 27 Italy Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 28 Italy Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 29 Spain Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 30 Spain Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 31 Spain Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 32 Denmark Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 33 Denmark Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 34 Denmark Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 35 Sweden Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 36 Sweden Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 37 Sweden Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 38 Norway Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 39 Norway Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 40 Norway Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 45 Japan Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 46 Japan Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 47 Japan Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 48 China Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 49 China Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 50 China Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 51 India Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 52 India Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 53 India Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 54 Australia Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 55 Australia Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 56 Australia Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 57 South Korea Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 58 South Korea Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 59 South Korea Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 60 Thailand Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 61 Thailand Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 62 Thailand Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 63 Latin America Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 64 Latin America Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 65 Latin America Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 66 Latin America Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 67 Brazil Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 68 Brazil Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 69 Brazil Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 70 Mexico Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 71 Mexico Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 72 Mexico Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 73 Argentina Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 74 Argentina Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 75 Argentina Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 76 MEA Anti-Obesity Medication Market, by country, 2021 - 2033 (USD Million)
  • Table 77 MEA Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 78 MEA Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 79 MEA Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 80 South Africa Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 81 South Africa Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 82 South Africa Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 86 UAE Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 87 UAE Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 88 UAE Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Anti-Obesity Medication Market, by Product, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Anti-Obesity Medication Market, by Mechanism of Action, 2021 - 2033 (USD Million)
  • Table 91 Kuwait Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Anti-Obesity Medication Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain - based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Anti-Obesity Medication Market snapshot (2023)
  • Fig. 9 Anti-Obesity Medication Market: Segment snapshot (2023)
  • Fig. 10 Competitive Insights (2023)
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Anti-Obesity Medication Market driver impact
  • Fig. 15 Anti-Obesity Medication Market restraint impact
  • Fig. 16 Clinical chemistry industry challenges
  • Fig. 17 Porter's Five Forces Analysis
  • Fig. 18 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 19 Strategic alliance analysis
  • Fig. 20 Recent developments & impact analysis, by key market participants
  • Fig. 21 Key company market share analysis, 2023
  • Fig. 22 Company market position analysis
  • Fig. 23 Definition and scope, by product
  • Fig. 24 Product market share analysis, 2023 & 2030
  • Fig. 25 Segment dashboard
  • Fig. 26 Global Anti-Obesity Medication Market, by product, 2021 - 2033 (USD Million)
  • Fig. 27 Approved market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 28 Bupropion - naltrexone (Contrave) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 29 Liraglutide (Orlistat) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 30 Orlistat market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 31 Xenical market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 32 Alli market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 33 Phentermine - topiramate (Qsymia) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 34 Semaglutide (Wegovy) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 35 Tirzepatide (Zepbound) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 36 Setmelanotide (Imcivree) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 37 Off Label market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 38 Semaglutide (Ozempic) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 39 Liraglutide (Victoza) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 40 Dulaglutide (Trulicity) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 41 Topiramate (Dulaglutide (Trulicity)) market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 42 Others market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 43 Definition and scope, by Distribution Channel
  • Fig. 44 Distribution Channel market share analysis, 2023 & 2030
  • Fig. 45 Segment dashboard
  • Fig. 46 Global Anti-Obesity Medication Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Fig. 47 Retail Pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 48 Hospital Pharmacies market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 49 Others market size & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 50 North America market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 51 U.S. market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 52 Canada market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 53 Europe market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 54 UK market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 55 Germany market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 56 Spain market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 57 France market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 58 Italy market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 59 Sweden market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 60 Denmark market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 61 Norway market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 62 Asia Pacific market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 63 China market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 64 Japan market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 65 India market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 66 Australia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 67 South Korea market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 68 Thailand market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 69 Latin America market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 70 Brazil market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 71 Mexico market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 72 Argentina market size, & forecasts and trend analysis, 2021 to 2033 (USD Million))
  • Fig. 73 Middle East and Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 74 South Africa market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 75 Saudi Arabia market size, & forecasts and trend analysis, 2021 to 2033 (USD Million)
  • Fig. 76 UAE market size, & forecasts and trend analysis, 2021 to 2033(USD Million)
  • Fig. 77 Kuwait market size, & forecasts and trend analysis, 2021 to 2033(USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!